sumatriptan has been researched along with Migraine with Aura in 20 studies
Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.
sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.
Migraine with Aura: A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| " From November 2001 to March 2002, patients meeting International Headache Society criteria for migraine (with > or =2 of the following: unilateral location, pulsating quality, moderate or severe intensity, aggravation by moderate physical activity; and > or =1 of: phonophobia and phonophobia, nausea and/or vomiting) and with no evidence of bacterial rhinosinusitis were enrolled and randomized in a 1:1 ratio via computer-generated randomization schedule to receive either 1 sumatriptan 50-mg tablet or matching placebo tablet." | 5.12 | Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study. ( Ames, M; Blumenthal, H; Ishkanian, G; Richardson, MS; Webster, CJ, 2007) |
| "Sumatriptan has been developed as a new tablet formulation to enhance the rate of systemic drug delivery by improving tablet disintegration and drug dispersion relative to those of conventional tablets." | 2.71 | Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. ( Boswell, D; Bullman, J; Dow, A; Lewis, A; Sidhu, J; Summers, SJ; Walls, C, 2004) |
| "Almotriptan malate is a novel, selective serotonin(1B/D) agonist, or triptan, developed for the abortive treatment of migraine." | 2.70 | Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. ( Gomez-Mancilla, B; Grosz, DE; Jirgens, KJ; Rowland, CR; Spierings, EL; Whaley, FS, 2001) |
| "These structures could play the role of migraine attack generators, modulating intrinsic vascular tone and central pain transmission." | 2.43 | [Positron emission tomographic studies of migraine]. ( Chollet, F; Denuelle, M; Fabre, N; Géraud, G; Payoux, P, 2005) |
| "A similar pattern was observed for migraine-free results 2 hours postdose (50 mg, 42%; 100 mg, 47%; placebo, 20%; P < 0." | 2.43 | Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. ( Ames, M; Landy, S; Richardson, M; Winner, P, 2005) |
| "Topiramate was effective long-term." | 1.39 | Musical murmurs on transcranial ultrasound in childhood migraine with aura. ( Kraft, P; Müllges, W, 2013) |
| "A 60-year-old woman with secondary chronic cluster headache had increased serum ferritin and serum transferrin saturation and was homozygous for the C282Y mutation in the HFE gene, which is indicative of hereditary haemochromatosis." | 1.31 | Hereditary haemochromatosis in two cousins with cluster headache. ( Bjerve, KS; Hagen, K; Stovner, LJ; Waage, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 11 (55.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liktor-Busa, E | 1 |
| Blawn, KT | 1 |
| Kellohen, KL | 1 |
| Wiese, BM | 1 |
| Verkhovsky, V | 1 |
| Wahl, J | 1 |
| Vivek, A | 1 |
| Palomino, SM | 1 |
| Davis, TP | 1 |
| Vanderah, TW | 1 |
| Largent-Milnes, TM | 1 |
| Tang, C | 1 |
| Unekawa, M | 1 |
| Kitagawa, S | 1 |
| Takizawa, T | 1 |
| Kayama, Y | 1 |
| Nakahara, J | 1 |
| Shibata, M | 1 |
| Jarvis, S | 1 |
| Dassan, P | 1 |
| Piercy, CN | 1 |
| Kraft, P | 1 |
| Müllges, W | 1 |
| Ward, TN | 1 |
| Hansen, JM | 1 |
| Goadsby, PJ | 1 |
| Charles, A | 1 |
| Lampl, C | 1 |
| Huber, G | 1 |
| Haas, S | 1 |
| Rittberger, E | 1 |
| Diener, HC | 1 |
| Cady, R | 2 |
| Banks, J | 1 |
| Nett, RB | 1 |
| Goldstein, J | 1 |
| Bennett, N | 1 |
| Turner, IM | 1 |
| Ruoff, GE | 1 |
| Landy, SH | 1 |
| Farmer, K | 1 |
| Juhász, M | 1 |
| Tarrasch, J | 1 |
| Runken, MC | 1 |
| Weidmann, E | 1 |
| Unger, J | 1 |
| Blair, S | 1 |
| Friesen, C | 1 |
| Hart, C | 1 |
| D'Andrea, G | 1 |
| Terrazzino, S | 1 |
| Leon, A | 1 |
| Fortin, D | 1 |
| Perini, F | 1 |
| Granella, F | 1 |
| Bussone, G | 1 |
| Walls, C | 1 |
| Lewis, A | 1 |
| Bullman, J | 1 |
| Boswell, D | 1 |
| Summers, SJ | 1 |
| Dow, A | 1 |
| Sidhu, J | 1 |
| Géraud, G | 1 |
| Denuelle, M | 1 |
| Fabre, N | 1 |
| Payoux, P | 1 |
| Chollet, F | 1 |
| Winner, P | 1 |
| Landy, S | 1 |
| Richardson, M | 1 |
| Ames, M | 2 |
| Porter, G | 1 |
| Shaw, T | 1 |
| Ryan, CJ | 1 |
| Ishkanian, G | 1 |
| Blumenthal, H | 1 |
| Webster, CJ | 1 |
| Richardson, MS | 1 |
| Baezner, H | 1 |
| Steinke, W | 1 |
| Daffertshofer, M | 1 |
| Hennerici, M | 1 |
| Dahlöf, C | 1 |
| Boska, MD | 1 |
| Welch, KM | 1 |
| Schultz, L | 1 |
| Nelson, J | 1 |
| Spierings, EL | 1 |
| Gomez-Mancilla, B | 1 |
| Grosz, DE | 1 |
| Rowland, CR | 1 |
| Whaley, FS | 1 |
| Jirgens, KJ | 1 |
| Stovner, LJ | 1 |
| Hagen, K | 1 |
| Waage, A | 1 |
| Bjerve, KS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "An Open-label Study to Evaluate Completeness of Response Following Treatment With Treximet™ for Migraine"[NCT00893737] | Phase 4 | 147 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.~The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication)." (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Pain Score | Associated Symptoms Score | Limbic Symptoms Score | Functionality Score | |
| Treximet | 0.17 | 0.07 | 0.03 | 0.10 |
Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Efficacy | Functionality | Ease of Use | Cost | |
| Treximet | 8.61 | 13.86 | 2.76 | 7.28 |
CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours. (NCT00893737)
Timeframe: Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)
| Intervention | Percent of Participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| How often 1 dose relieves headache pain | How often 1 dose relieves neck/shoulder pain | How often 1 dose relieves nausea | How often 1 dose relieves light sensitivity | How often 1 dose relieves sound sensitivity | How often 1 dose relieves irritability | How quickly can you concentrate or think clearly | How quickly can you resume normal activities | How quickly can you function normally | How quickly do you feel completely normal | Confidence 1 dose will relieve migraine in 2 hours | Confidence migraine will not return in 24 hours | |
| Treximet | 42 | 52 | 43 | 42 | 45 | 36 | 31 | 32 | 32 | 36 | 33 | 38 |
2 reviews available for sumatriptan and Migraine with Aura
| Article | Year |
|---|---|
[Positron emission tomographic studies of migraine].
Topics: Cerebrovascular Circulation; Humans; Migraine Disorders; Migraine with Aura; Muscle Tonus; Positron- | 2005 |
Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; | 2005 |
9 trials available for sumatriptan and Migraine with Aura
| Article | Year |
|---|---|
Reduced efficacy of sumatriptan in migraine with aura vs without aura.
Topics: Adult; Databases, Factual; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Migraine wi | 2015 |
Difference in triptan effect in patients with migraine and early allodynia.
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Face; Female; Humans; Male; Mid | 2008 |
Multi-center comparison of response to a single tablet of sumatriptan 85 mg and naproxen 500 mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combi | 2011 |
An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations.
Topics: Administration, Intranasal; Administration, Oral; Adult; Female; Humans; Injections, Subcutaneous; M | 2003 |
Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; | 2004 |
Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dizziness; Double-Blind Method; Female; Humans; Male; | 2007 |
How to assess patient preference of migraine treatments.
Topics: Adult; Analgesics; Cross-Over Studies; Female; Humans; Male; Middle Aged; Migraine Disorders; Migrai | 1999 |
Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects.
Topics: Adenosine Triphosphate; Adult; Creatine Kinase; Energy Metabolism; Female; Humans; Magnetic Resonanc | 2000 |
Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cardiovascular System; Chi-Square Distribution; Doubl | 2001 |
9 other studies available for sumatriptan and Migraine with Aura
| Article | Year |
|---|---|
Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake.
Topics: Animals; Blood-Brain Barrier; Brain; Central Nervous System; Cortical Spreading Depression; Disease | 2020 |
Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant.
Topics: Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Cere | 2020 |
Managing migraine in pregnancy.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Female; Humans; Migraine with Aura; Pre | 2018 |
Musical murmurs on transcranial ultrasound in childhood migraine with aura.
Topics: Anticonvulsants; Basilar Artery; Brain; Child; Echoencephalography; Female; Fructose; Humans; Migrai | 2013 |
Does the presence of aura inform us regarding migraine severity and response to treatment?
Topics: Dihydroergotamine; Female; Humans; Male; Migraine with Aura; Migraine without Aura; Sumatriptan; Vas | 2015 |
Elevated levels of circulating trace amines in primary headaches.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Cluster Headache; Diet; Female; Headache; H | 2004 |
Fugue associated with migraine.
Topics: Adult; Amnesia; Brain; Humans; Magnetic Resonance Imaging; Male; Migraine with Aura; Sumatriptan; To | 2007 |
Vasoneuronal coupling in migraineurs after subcutaneous sumatriptan: a TCD study.
Topics: Adult; Blood Flow Velocity; Cohort Studies; Female; Humans; Male; Migraine with Aura; Posterior Cere | 1999 |
Hereditary haemochromatosis in two cousins with cluster headache.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Stem; Calcium Channel Blockers; Cluster Headac | 2002 |